Exploring Real-World Atopic Dermatitis Treatment Patterns : Episode 5

Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis

April 14, 2025

By Gary M. Owens, MD
Lawrence Eichenfield, MD

Opinion

Video

Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic dermatitis, demonstrating sustained disease control, reduced healthcare utilization, decreased steroid dependency, improved medication adherence, and consistent safety outcomes across diverse patient demographics and disease severities compared to conventional treatments.

EP: 1.Key Background Information on Atopic Dermatitis

EP: 2.Study Design and Important Baseline Characteristics

EP: 3.Results and Takeaways From a 12-month Claims Analysis of Ruxolitinib

EP: 4.18-Month Retrospective Claims Analysis Study Information on Ruxolitinib

EP: 5.Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis

EP: 6.Important Takeaways Regarding the Utilization of Ruxolitinib

EP: 7.Exploring Real-World Atopic Dermatitis Treatment Patterns | Written Recap

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.